Agenus
Agenus

Agenus

Biotechnology
WebsiteInvestor RelationsSEC
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

$300.7M

Market Cap • 10/15/2026

1999

(27 years)

Founded

2000

(26 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

2,3

P/EBITDA

7,3

P/OCF

—

P/FCF

—

P/E

2,6

BVPS

—

EPS

2,5

Market Cap

Market Cap

300,7M

EV

322,7M

EV/Revenue

2,4

EV/EBITDA

7,9

EV/EBIT

8,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-13,3%

Total Yield

-13,3%

Payout

0%

Retained Earnings

-2,1B

Profitability

Gross Margin

99,5%

EBITDA Margin

30,8%

EBIT Margin

27,3%

Net Margin

69,3%

D&A/EBITDA

0%

R&D/Revenue

43,5%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

12,5%

% Goodwill

14%

ROE

—

ROIC

23,5%

Growth

CAGR Revenue 5Y

14,1%

CAGR OCF 5Y

-9,9%

Leverage

N.D./EBITDA

0,5

Debt/Equity

0%

Current Ratio

0,3

Quick Ratio

0,2

Interest Coverage

61,3%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium